Preliminary evidence of improvement of depressive symptoms but not impulsivity in cluster B personality disorder patients treated with quetiapine: An open label trial

Pharmacopsychiatry

Volumn 41, Issue 5, 2008, Pages 176-181

  Roepke, Stefan ^a   Merkl, A ^a   Dams, A ^a   Ziegenhorn, A ^a,b   Anghelescu, I G ^a   Heuser, I ^a   Lammers, C H ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PSYCHOTROPIC AGENT; QUETIAPINE; TRIMIPRAMINE;

ADULT; AGITATION; ANTICHOLINERGIC SYNDROME; ARTICLE; BARRATT IMPULSIVENESS SCALE; BECK DEPRESSION INVENTORY; BORDERLINE STATE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HAMILTON SCALE; HISTRIONIC PERSONALITY DISORDER; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; IMPULSIVENESS; MENTAL DISEASE; MONOTHERAPY; MORNING DOSAGE; NARCISSISM; NAUSEA; NEUROMUSCULAR DISEASE; NOSE CONGESTION; OPEN STUDY; PATIENT COMPLIANCE; PERSONALITY DISORDER; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; PSYCHOSIS; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DEPRESSION; DIBENZOTHIAZEPINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMPULSIVE BEHAVIOR; MALE; MIDDLE AGED; PERSONALITY DISORDERS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 54749118885     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1076730     Document Type: Article

References (45)

1. Adityanjee, Schulz SC. Clinical use of quetiapine in disease states other than schizophrenia. J Clin Psychiatry 2002; 63 (Suppl 13): 32-38
2. American Psychiatric Association. Practical guidelines for the treatment of patients with borderline personality disorder. Am J Psychiatry 2001; 158: 1-52
3. Barratt ES. Impulsiveness substrates: Arousal and information processing. In: Spence JT and Izard CE Motivation, Emotion and personality. North-Holland: Elsevier Science 1985; 137-146
4. Barratt ES, Stanford MS, Kent TA, Felthous A. Neuropsychological and cognitive psychophysiological substrates of impulsive aggression. Biol Psychiatry 1997; 41: 1045-1061
5. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory of measuring depression. Arch Gen Psychiatry 1961; 4: 561-571
6. Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: A pilot study. J Clin Psychiatry 2006; 67: 1042-1046
7. Bogenschutz MP, Nurnberg HG. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry 2004; 65: 104-109
8. 11C]raclopride/positron emission tomography study in healthy men. Arch Gen Psychiatry 2006; 63: 1386-1395
9. Chengappa KN, Ebeling T, Kang JS, Levine J, Parepally H. Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder. J Clin Psychiatry 1999; 60: 477-484
10. Dalley JW, Fryer TD, Brichard L, Robinson ES, Theobald DE, Laane K, Pena Y, Murphy ER, Shah Y, Probst K, Abakumova I, Aigbirhio FI, Richards HK, Hong Y, Baron JC, Everitt BJ, Robbins TW. Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. Science 2007; 315: 1267-1270
11. Davidson RJ, Putnam KM, Larson CL. Dysfunction in the neural circuitry of emotion regulation: a possible prelude to violence. Science 2000; 289: 591-594
12. Dougherty DM, Bjork JM, Huckabee HC, Moeller FG, Swann AC. Laboratory measures of aggression and impulsivity in women with borderline personality disorder. Psychiatr Res 1999; 85: 315-326
13. First MB, Gibbon M, Spitzer RL, Williams JBW. Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II) 1996
14. Fossati A, Barratt ES, Borroni S, Villa D, Grazioli F, Maffei C. Impulsivity. aggressiveness, and DSM-IV personality disorders. Psychiatr Res 2007; 149: 157-167
15. Frankenburg FR, Zanarini MC. The association between borderline personality disorder and chronic medical illnesses, poor health-related lifestyle choices, and costly forms of health care utilization. J Clin Psychiatry 2004; 65: 1660-1665
16. Gao K, Muzina D, Gajwani P, Calabrese JR. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: A review. J Clin Psychiatry 2006; 67: 1327-1340
17. Guy W. ECDEU Assessment Manual for Psychopharmacology (DHEW Publication No. ADM 76-338), U.S. Department of Health, Education & Welfare, Rockville, MD 1976; 158-169
18. Hamilton A. Diagnosis and rating of anxiety. Br J Psychiatry 1959; 3: 67-69
19. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278-296
20. Links PS, Heslegrave R, Reekum R van. Impulsivity: core aspect of borderline personality disorder. J Personal Disord 1999; 13: 1-9
21. Linnoila M. Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from nonimpulsive violent behavior. Life Sci 1983; 33: 2609-2614
22. Looper KJ, Paris J. What dimensions underlie Cluster B personality disorders? Comprehen Psychiatry 2000; 41: 432-437
23. Markovitz PJ. Recent trends in the pharmacotherapy of personality disorders. J Personal Disord 2004; 18: 90-101
24. MacGlashan TH, Grilo CM, Sanislow CA, Ralevski E, Morey LC, Gunderson JG, Skodol AE, Shea MT, Zanarini MC, Bender D, Stout RL, Yen S, Pagano M. Two-year prevalence and stability of individual DSM-IV criteria for schizotypal, borderline, avoidant, and obsessive-compulsive personality disorders: toward a hybrid model of axis II disorders. Am J Psychiatry 2005; 162: 883-889
25. Mobascher A, Mobascher J, Schlemper V, Winterer G, Malevani J. Aripiprazole pharmacotherapy of borderline personality disorder. Pharmacopsychiatry 2006; 39: 111-112
26. Mulder RT, Joyce PR, Sullivan PF, Bulik CM, Carter FA. The relationship among three models of personality psychopathology: DSM-II-R personality disorder. TCI scores and DSQ defences. Psychol Med 1999; 29: 943-951
27. Nemeroff CB. Use of atypical antipsychotics in refractory depression and anxiety. J Clin Psychiatry 2005; 66: 13-21
28. New AS, Hazlett EA, Buchsbaum MS, Goodman M, Reynolds D, Mitropoulou V, Sprung L, Shaw RB, Koenigsberg H, Platholi J, Silverman J, Siever LJ. Blunted prefrontal cortical 18fluorodeoxyglucose positron emission tomography response to meta-chlorophenylpiperazine in impulsive aggression. Arch Gen Psychiatry 2002; 59: 621-629
29. Nickel MK, Muehlbacher M, Nickel C, Kettler C, Pedrosa GF, Bachler E, Buschmann W, Rother N, Fartacek R, Egger C, Anvar J, Rother WK, Loew TH, Kaplan P. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2006; 163: 833-838
30. Pascual JC, Madre M, Soler J, Barrachina J, Campins MJ, Alvarez E, Pérez V. Injectable atypical antipsychotics for agitation in borderline personality disorder. Pharmacopsychiatry 2006; 39: 117-118
31. Patton JH, Stanfrod MS, Barratt ES. Factor structure of the Barratt impulsiveness scale. J Clin Psychol 1995; 51: 768-774
32. Perrella C, Carrus D, Costa E, Schifano F. Quetiapine for the treatment of borderline personality disorder; an open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 158-163
33. Rocca P, Marchiaro L, Cocuzza F, Bogetto F. Treatment of borderline personality disorder with risperidone. J Clin Psychiatry 2002; 63: 241-244
34. Schulz SC. The promise of atypical antipsychotics for borderline personality disorders. Presented at the 115th annual meeting of the American Psychiatric Association May 18-23 Philadelphia, Pa 2002
35. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59: 22-33
36. Skodol AE, Siever LJ, Livesly WJ, Gunderson JG, Pfohl B, Widiger TA. The borderline diagnosis II: biology, genetics, and clinical course. Biol Psychiatry 2002; 51: 951-963
37. Soler J, Pascual JC, Campins J, Barrachina J, Puigdemont D, Alvarez E, Perez V. Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry 2005; 162: 1221-1224
38. Soubrie P. Serotonergic neurons and behaviour. J Pharmacol 1986; 17: 107-112
39. Steel Z, Blaszczynski A. Impulsivity, personality disorders and pathological gambling severity. Addiction 1998; 93: 895-905
40. Villeneuve E, Lemelin S. Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target. J Clin Psychiatry 2005; 66: 1298-1303
41. Walker C, Thomas J, Allen TS. Treating impulsivity, irritability, and aggression of antisocial personality disorder with quetiapine. Int J Offender Ther Comp Criminol 2003; 47: 556-567
42. Zanarini MC. Borderline personality as an impulse spectrum disorder. In Paris J (ed). Borderline Personality Disorder: Etiology and Treatment. Washington, DC: American Psychiatric Press 1993; 67-86
43. Zanarini M, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry 2001; 62: 849-854
44. Zanarini M, Frankenburg FR, Parachini EA. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry 2004; 65: 903-907
45. Zoccolillo M, Pickles A, Quinton D, Rutter M. The outcome of childhood conduct disorder: implications for defining adult personality disorder and conduct disorder. Psychol Med 1992; 22: 971-986